Zobrazit minimální záznam

Iron chelators as mitophagy agents: Potential and limitations

dc.contributor.authorBrogyányi, Tereza
dc.contributor.authorKejík, Zdeněk
dc.contributor.authorVeselá, Kateřina
dc.contributor.authorDytrych, Petr
dc.contributor.authorHoskovec, David
dc.contributor.authorMasařík, Michal
dc.contributor.authorBabula, Petr
dc.contributor.authorKaplánek, Robert
dc.contributor.authorPřibyl, Tomáš
dc.contributor.authorZelenka, Jaroslav
dc.contributor.authorRuml, Tomáš
dc.contributor.authorVokurka, Martin
dc.contributor.authorMartásek, Pavel
dc.contributor.authorJakubek, Milan
dc.date.accessioned2024-11-12T11:41:13Z
dc.date.available2024-11-12T11:41:13Z
dc.date.issued2024
dc.identifier.urihttps://hdl.handle.net/20.500.14178/2690
dc.description.abstractMitochondrial autophagy (mitophagy) is very important process for the maintenance of cellular homeostasis, functionality and survival. Its dysregulation is associated with high risk and progression numerous serious diseases (e.g., oncological, neurodegenerative and cardiovascular ones). Therefore, targeting mitophagy mechanisms is very hot topic in the biological and medicinal research. The interrelationships between the regulation of mitophagy and iron homeostasis are now becoming apparent. In short, mitochondria are central point for the regulation of iron homeostasis, but change in intracellular cheatable iron level can induce/repress mitophagy. In this review, relationships between iron homeostasis and mitophagy are thoroughly discussed and described. Also, therapeutic applicability of mitophagy chelators in the context of individual diseases is comprehensively and critically evaluated.en
dc.language.isoen
dc.relation.urlhttps://doi.org/10.1016/j.biopha.2024.117407
dc.rightsCreative Commons Uveďte původ 4.0 Internationalcs
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.titleIron chelators as mitophagy agents: Potential and limitationsen
dcterms.accessRightsopenAccess
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/legalcode
dc.date.updated2024-11-12T11:41:13Z
dc.subject.keywordMitophagyen
dc.subject.keywordIron heomeostaisen
dc.subject.keywordIron chelatorsen
dc.subject.keywordCanceren
dc.subject.keywordNeurodegenerative diseasesen
dc.subject.keywordCardiovascular diseasesen
dc.subject.keyworden
dc.identifier.eissn1950-6007
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5102
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5104
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5107
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//SVV260637
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//SVV260521
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/UK/COOP/COOP
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM/LM/LM2023053
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/TA0/TN/TN02000109
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MZ0/NU/NU22-08-00160
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MZ0/NU/NU21-08-00407
dc.date.embargoStartDate2024-11-12
dc.type.obd73
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doi10.1016/j.biopha.2024.117407
dc.identifier.utWos001314505400001
dc.identifier.eidScopus2-s2.0-85203549767
dc.identifier.obd652962
dc.identifier.pubmed39265234
dc.subject.rivPrimary30000::30100
dc.subject.rivSecondary10000::10600
dcterms.isPartOf.nameBiomedicine & Pharmacotherapy
dcterms.isPartOf.issn0753-3322
dcterms.isPartOf.journalYear2024
dcterms.isPartOf.journalVolume179
dcterms.isPartOf.journalIssueOctober
uk.faculty.primaryId108
uk.faculty.primaryName1. lékařská fakultacs
uk.faculty.primaryNameFirst Faculty of Medicineen
uk.faculty.secondaryId53
uk.faculty.secondaryNameVšeobecná fakultní nemocnice v Prazecs
uk.faculty.secondaryNameVšeobecná fakultní nemocnice v Prazeen
uk.department.primaryId100025448551
uk.department.primaryNameBIOCEV 1. lékařské fakultycs
uk.department.primaryNameBIOCEV of the 1st Faculty of Medicineen
uk.department.secondaryId1522
uk.department.secondaryId5000002594
uk.department.secondaryId1496
uk.department.secondaryId1508
uk.department.secondaryId5000002603
uk.department.secondaryNameKlinika pediatrie a dědičných poruch metabolismu 1. LF a VFNcs
uk.department.secondaryNameDepartment of Paediatrics and Inherited Metabolic Disorders 1. LF UK a VFNen
uk.department.secondaryNameI. chirurgická klinika - břišní, hrudní a úrazová chirurgie 1.LF a VFNcs
uk.department.secondaryNameI. chirurgická klinika - břišní, hrudní a úrazová chirurgie 1.LF a VFNen
uk.department.secondaryNameÚstav patologické fyziologie 1. LF UKcs
uk.department.secondaryNameInstitute of Pathological Physiologyen
uk.department.secondaryNameI. chirurgická klinika – břišní, hrudní a úrazové chirurgie 1. LF UK a VFNcs
uk.department.secondaryName1st Department of Surgery – Department of Abdominal, Thoracic Surgery and Traumatologyen
uk.department.secondaryNameKlinika pediatrie a dědičných poruch metabolismu 1.LF a VFNcs
uk.department.secondaryNameKlinika pediatrie a dědičných poruch metabolismu 1.LF a VFNen
dc.type.obdHierarchyCsČLÁNEK V ČASOPISU::článek v časopisu::přehledový článekcs
dc.type.obdHierarchyEnJOURNAL ARTICLE::journal article::summarizing articleen
dc.type.obdHierarchyCode73::152::205en
uk.displayTitleIron chelators as mitophagy agents: Potential and limitationsen


Soubory tohoto záznamu

Thumbnail

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam